Skip to main content
Clinical Trials/NCT07151989
NCT07151989Enrolling By InvitationNot Applicable

Influence of Original Native Mitral Valve Lesion (Stenosis or Steno-insufficiency vs. Insufficiency) on Post-implant Structural Bioprosthetic Degeneration After Mitral Valve Replacement

Maastricht University Medical Center1 site in 1 country3,500 target enrollmentStarted: January 1, 2024Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Enrolling By Invitation
Enrollment
3,500
Locations
1
Primary Endpoint
Prosthesis degeneration due to physiological deterioration

Study Overview

Brief Summary

It aims to perform a retrospective, multi-center, observational study. All patients undergoing elective mitral valve replacement from 2012 to 2021 who met the inclusion criteria for the study (described in the dedicated section) will be enrolled in the study. These patients will be followed-up as part of routine care, and information about the clinical status, NYHA functional class, possible rehospitalization, possible cardiovascular events and postoperative echocardiography will be available for analysis. Once consent is given, and if required by local governance, pre-, intra- and post-operative data will be collected in a dedicated, structured, database.

Detailed Description

It aims to perform a retrospective, multi-center, observational study. All patients undergoing elective mitral valve replacement from 2012 to 2021 who met the inclusion criteria for the study (described in the dedicated section) will be enrolled in the study. These patients will be followed-up as part of routine care, and information about the clinical status, NYHA functional class, possible rehospitalization, possible cardiovascular events and postoperative echocardiography will be available for analysis. Once consent is given, and if required by local governance, pre-, intra- and post-operative data will be collected in a dedicated, structured, database.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Other

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥ 18 years;
  • Patients who underwent isolated mitral valve replacement for stenosis or regurgitation
  • Signed informed consent, inclusive of release of medical information where required by local governance.

Exclusion Criteria

  • - Aortic and mitral valve replacement associated with surgery of ascending aorta/aortic root;
  • Aortic and mitral valve replacement associated with other cardiac valve surgery (apart from arrythmia-related ablation or procedures);
  • Previous cardiac surgery of any kind;
  • Surgery for acute endocarditis
  • Surgery for Type A aortic dissection
  • Participation in another clinical trial that could interfere with the endpoints of this study.
  • Pregnant or breastfeeding at time of screening.

Outcomes

Primary Outcomes

Prosthesis degeneration due to physiological deterioration

Time Frame: 20 years

Echocardiographic paramters will be used. Quantitative and qualitative measurments swill be implied. The measurment used are listed below: 1. Morphological Assessment (2D / 3D TTE \& TEE) Leaflet morphology: thickness, mobility, calcification, pannus, tears, perforations. Bioprosthetic ring/annulus: dehiscence, rocking motion, paravalvular defects. Presence of thrombus, pannus, or vegetation. Structural valve deterioration (SVD) features: leaflet thickening, restricted opening, abnormal motion. 2. Hemodynamic Assessment (Doppler Echocardiography) Mitral inflow pattern (continuous-wave Doppler across prosthesis): Peak velocity (m/s) Mean transprosthetic gradient (mmHg) - heart-rate dependent Pressure half-time (PHT, ms) - limited use in prosthetic valves, but can suggest stenosis Effective orifice area (EOA) (via continuity equation or PHT-derived, cautiously interpreted). Doppler Velocity Index (DVI) = LVOT VTI / Prosthetic MV VTI (helps detect obstruction independent of fl

Secondary Outcomes

  • Long term survival(20 years)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Roberto Lorusso

Prof. MD PhD

Maastricht University Medical Center

Study Sites (1)

Loading locations...

Similar Trials

Influence of Original Native Mitral Valve... | Clinical Trial